CN105106976B - A kind of Iodixanol parenteral solution and preparation method thereof - Google Patents
A kind of Iodixanol parenteral solution and preparation method thereof Download PDFInfo
- Publication number
- CN105106976B CN105106976B CN201510513894.9A CN201510513894A CN105106976B CN 105106976 B CN105106976 B CN 105106976B CN 201510513894 A CN201510513894 A CN 201510513894A CN 105106976 B CN105106976 B CN 105106976B
- Authority
- CN
- China
- Prior art keywords
- iodixanol
- acid
- parenteral solution
- parenteral
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to technical field of medicine, discloses a kind of Iodixanol parenteral solution and preparation method thereof.Iodixanol parenteral solution of the present invention, its component contain：Iodixanol, sodium chloride, sodium tartrate, water for injection is added to full dose, is finally adjusted to suitable pH scopes with acid.Compared with prior art, the type and quantity that auxiliary material adds in Iodixanol parenteral solution of the invention are greatly decreased, and the viscosity of parenteral solution further reduces, and improve the compliance of clinical patient application.Meanwhile tested by high-temperature sterilization, low temperature frozen process experiment and irritation test etc. are investigated, and Iodixanol parenteral solution steady quality of the invention, blood vessel irritation is small, complies fully with the demand of safe medication.
Description
Technical field
The invention belongs to technical field of medicine, parenteral solution and its preparation side more particularly to a kind of Iodixanol
Method.
Background technology
Since the appearance of first diodone amidotrizoic acid of or so nineteen fifty, there is more than ten kinds of iodine radiography at present
Agent is widely used in clinic, this kind of diodone can be divided into three classes according to permeability as diagnostic reagent：The first kind is hypertonic iodine
Contrast agent, such as amidotrizoic acid, cardiografin etc., its osmotic pressure are 5~8 times of blood of human body；Second class is hypotonic diodone, bag
Including ionic dimer (such as Hwxabrix) and nonionic monomers, (such as iobitridol, iomeprol, Iopentol, Ioversol, iodine are general
Sieve amine etc.) its osmotic pressure is about 2 times of blood of human body；3rd class is isotonic diodone, i.e. nonionic dimer, iodine gram sand
Alcohol is one of outstanding representative therein, and its osmotic pressure and blood of human body are isotonic.
Non-ionic contrast agent is widely used in the market, from physicochemical property, nonionic has water solubility greatly,
The unionization in water, infiltration the advantages of forcing down, in terms of clinical practice, the toxicity incidence of non-ionic contrast agent and serious
Degree is significantly lower than ionic contrast agent, available for the angiogram at each position, IVU, and CT enhancings check etc., especially
It more shows in heavy dose of fast injection, the advantages of nonionic.The widely used nonionic of in the market is made
Shadow agent, wherein monomeric form have：Iopamidol, Ioversol, iomeprol, Iopromide, and current dimer is mainly iodine
Gram husky alcohol.
Iodixanol (Iodixanol), chemical name 5,5 '-((2- hydroxyls -1,3- propane) double (ethylenemines)) are double
(- 2,4,6- tri- iodo- 1,3- benzenedicarboxamides of N, N '-two (2,3- dihydroxypropyl), are a kind of new nonionic x-rays
Contrast agent, made available for angiocardiography, cerebral angiography, peripheral arterial radiography, abdominal angiography, IVU, vein
Shadow and CT enhancings check.Iodixanol parenteral solution Yuan Yan producers are the GE Healthcare AS of Norway, and trade name prestige regards
Parker, production is registered in multiple countries such as Britain, the U.S., Japan, France, Germany, Canada, Australia, 2002
Sold into China market.There are 50ml in GE Healthcare AS companies in the specification of the Iodixanol parenteral solution of Discussion on Chinese Listed:
16g(I)、100ml:32g (II) etc..At present, the country has the permanent auspicious medicine in Jiangsu, Yangtze River medicine company and Beijing North land medicine company
Preparation lists successively.
Regarded from disclosed prestige in Parker specification, we learn, the accessory package in the parenteral solution contains tromethamine, chlorination
Sodium, calcium chloride, Ethylenediaminetetraacetic Acid Calcium Salt, salt acid for adjusting pH, water for injection.From the point of view of production practices and clinical practice, such injection is also
The following defect be present：(1) inject that fluid viscosity is big, and excitant is strong during injection, and patient compliance is poor；(2) although Iodixanol
Contrasting effects it is notable, but because medicine easily receives the influence of polyvalent metal ion in itself, and produce the side reaction of iodine removing,
Cause product unstable, color transition yellowly easily occur, particulate matter increases phenomenon, causes the yield rate in production process
Lowly；(3) easily there are many adverse reaction symptoms such as allergy in parenteral solution.Clinical study results show, although nonionic is made
The adverse reaction of shadow agent is less than ionic contrast agent, but slight cacesthesia occurs often, and such as warm-cold sensitivity, abdominal pain is not
It is suitable, allergic reaction, slight respiratory tract and dermoreaction, in addition some patients can occur after radiography in a few hours to a couple of days it is tardy
The adverse reaction of type.
The content of the invention
The technical problems to be solved by the invention are to provide a kind of Iodixanol parenteral solution unlike the prior art, to
Solve some defects of existing parenteral solution mentioned above.The present invention additionally provides a kind of new side for preparing this kind of parenteral solution simultaneously
Method, can effectively solve Iodixanol draw it is moist strong, it is difficult to the problem of stirring and dissolving.
In original grinds prescription of the injection prestige regarding Parker, sodium chloride is isotonic regulator, for auxiliary adjustment Iodixanol
Solution is isotonic with blood of human body.Tromethamine is pH stabilizers, coordinates appropriate hydrochloric acid, and the pH of the parenteral solution can be made stable appropriate
In the range of.Mosatil is metal ion chelation agent, for be complexed in production process may chance and heavy metal ion, reduce
The side reaction of main ingredient.In view of application of the mosatil in injection may reduce blood calcium concentration, therefore original is ground in prescription and added
It is probably the certain calcium ion of supplement to add one of effect of calcium chloride, improves the shrinkage of heart, slows down the influence to cardiac function.
We carry out auxiliary material selection and the improvement of preparation technology are excellent on the basis of the specification prescription information that former triturate prestige regards Parker
Change.
In the present invention, a kind of new Iodixanol parenteral solution is we provided, its component includes：Iodixanol, chlorine
Change sodium, sodium tartrate, water for injection adds to full dose, adds acid for adjusting pH to 6.5~8.5.
Specifically, the composition of the parenteral solution is as follows, contains in every 100mL parenteral solutions：
Preferably, " acid " of addition is selected from：Tartaric acid, phosphoric acid, hydrochloric acid, acetic acid.It is particularly preferred that " acid " that adds is selected from
It is selected from：Tartaric acid.
Preferably, pH scopes are adjusted after acid adding is：PH6.9-7.6, particularly preferably, it may be selected from 7.2~7.4.
It is particularly preferred that the composition of the Iodixanol parenteral solution is, contain in every 100mL parenteral solutions：
It is particularly preferred that the composition of the Iodixanol parenteral solution is, contain in every 100mL parenteral solutions：
Present invention also offers a kind of method for preparing above-mentioned Iodixanol parenteral solution, and the preparation method is specifically comprising such as
Lower step：(1) water for injection boiled of a quarter is added in Agitation Tank, 58-63 DEG C is cooled to, puts into the wine of recipe quantity
After stone acid sodium stirring and dissolving 0.5h, Iodixanol, stirring and dissolving are put into batches；(2) 35-40 DEG C is cooled to, in material-compound tank
The sodium chloride of recipe quantity is added, while mends and adds to the full amount of water for injection into material-compound tank, adds acid for adjusting pH to 6.9~7.6；(3)
Add activated carbon, dosage is 0.2~0.8wt% of parenteral solution, uses 0.5 μm of stud successively after stirring 15min, 0.45 μm is filtered
Device carries out being filtered to remove activated carbon；(4) finally sterilized (115 DEG C, 30min), lamp inspection, labeling, packaging.Wherein, addition
" acid " can be：Tartaric acid, hydrochloric acid, particularly preferably phosphoric acid, tartaric acid.The optimized scope for adjusting pH value is 7.2~7.4.
Iodixanol parenteral solution of the present invention can be used for preparing the medical usage among x-ray contrast agent, the X ray
Contrast agent is particularly applicable to angiocardiography, cerebral angiography, peripheral arterial radiography, abdominal angiography, IVU, quiet
Arteries and veins radiography and CT enhancings check.
Technical solution of the present invention achieves following beneficial technique effect
(1) grope through experiment, it has been found that the combination of sodium tartrate and tartaric acid can not only can effectively stablize
PH is avoided that, using the pH adjusting agent tromethamine with pharmacological activity, tromethamine is non-in the range of 6.9-7.6
The buffer base (BB) of sodium, reacts in body fluid with water, and makes its reduction, suitable for metabolic acid mass formed by blood stasis and respiratory acidaemia, ammonia
Butantriol side effect can not be ignored, and some are than more serious, not allow for drug of first choice, excitant when correcting metabolic acidosis
It is relatively strong, during intravenous infusion, if leaking in necrosis outside blood vessel, can be caused, and Vein thrombosis can be caused scorching.We use tartaric acid
After salt replaces, it is possible to prevente effectively from the adverse reaction that tromethamine triggers.
(2) original is ground and metal ion chelation agent mosatil has been used in prescription, but mosatil is being injected intravenously
Use in liquid need to be controlled strictly.The teacher that medicine evaluates center was also once write articles and refer to be complexed using edetic acid(EDTA) sodium salt
Calcium ion in blood, cause blood calcium relatively low.The calcium chloride that original is ground in prescription is based on supplementing a certain amount of calcium and adding
, the shrinkage of heart can be strengthened, slow down the influence to cardiac function.The sodium tartrate and the group of tartaric acid used in the present invention
During contract also have certain chelated polyvalent metal ion ability, through subsequent embodiment experiment show, can substitute completely according to
Ground acid calcium sodium uses, moreover it is possible to avoids adding unnecessary auxiliary material calcium chloride.
(3) in parenteral solution preparation process, Iodixanol is added in EWNN solution, Iodixanol can be avoided to hold
The easily aggregation pockets of phenomenon of adhesion.
(4) compared to former triturate, the type and quantity that auxiliary material adds are greatly decreased parenteral solution of the present invention, inject
The viscosity of liquid further reduces, and improves the compliance of clinical patient application.Meanwhile tested through follow-up high-temperature sterilization, low temperature
Frozen process experiment, and irritation test show that Iodixanol parenteral solution steady quality of the invention, excitant is small, complies fully with peace
The requirement of full medication.
Embodiment
In the examples below, the present invention will more specifically be explained, it should be appreciated that the following example is intended to illustrate hair
It is bright without to the scope of the present invention form any restrictions.
Embodiment 1
Injection formula：
According in the amplification production of aforementioned proportion, the disposable preparation amount of Iodixanol is 20L.
Preparation method：(1) water for injection boiled of a quarter is added in Agitation Tank, is cooled to 58~63 DEG C, is thrown
After the sodium tartrate stirring and dissolving 0.5h for entering recipe quantity, Iodixanol, stirring and dissolving are put into batches；(2) 35~40 are cooled to
DEG C, the sodium chloride of recipe quantity is added in material-compound tank, while mend and add to the full amount of water for injection into material-compound tank, add tartaric acid to adjust
PH to 7.2~7.4；(3) activated carbon is added, dosage is the 0.2-0.8wt% of parenteral solution, is stirred after 15min successively with 0.5 μm
Stud, 0.45 μm of filter carry out being filtered to remove activated carbon；(4) finally sterilized (115 DEG C, 30min), lamp inspection, labeling, bag
Dress.
Embodiment 2
Injection formula：
According in the amplification production of aforementioned proportion, the disposable preparation amount of Iodixanol is 20L.
Preparation method：(1) water for injection boiled of a quarter is added in Agitation Tank, is cooled to 58~63 DEG C, is thrown
After the sodium tartrate stirring and dissolving 0.5h for entering recipe quantity, Iodixanol, stirring and dissolving are put into batches；(2) 35~40 are cooled to
DEG C, the sodium chloride of recipe quantity is added in material-compound tank, while mend and add to the full amount of water for injection into material-compound tank, add tartaric acid to adjust
PH to 7.2~7.4；(3) activated carbon is added, dosage is 0.2~0.8wt% of parenteral solution, is stirred after 15min successively with 0.5 μ
M studs, 0.45 μm of filter carry out being filtered to remove activated carbon；(4) finally sterilized (115 DEG C, 30min), lamp inspection, labeling,
Packaging.
Embodiment 3
Injection formula：
According in the amplification production of aforementioned proportion, the disposable preparation amount of Iodixanol is 20L.
Preparation method：(1) water for injection boiled of a quarter is added in Agitation Tank, is cooled to 58~63 DEG C, is thrown
After the sodium tartrate stirring and dissolving 0.5h for entering recipe quantity, Iodixanol, stirring and dissolving are put into batches；(2) 35~40 are cooled to
DEG C, the sodium chloride of recipe quantity is added in material-compound tank, while mend and add to the full amount of water for injection into material-compound tank, phosphorate acid for adjusting pH
To 6.5~7.0；(3) activated carbon is added, dosage is 0.2~0.8wt% of parenteral solution, is stirred after 15min successively with 0.5 μm
Stud, 0.45 μm of filter carry out being filtered to remove activated carbon；(4) finally sterilized (115 DEG C, 30min), lamp inspection, labeling, bag
Dress.
Embodiment 4
Injection formula：
According in the amplification production of aforementioned proportion, the disposable preparation amount of Iodixanol is 20L.
Preparation method：(1) water for injection boiled of a quarter is added in Agitation Tank, is cooled to 58~63 DEG C, is thrown
After the sodium tartrate stirring and dissolving 0.5h for entering recipe quantity, Iodixanol, stirring and dissolving are put into batches；(2) 35~40 are cooled to
DEG C, the sodium chloride of recipe quantity is added in material-compound tank, while mend and add to the full amount of water for injection into material-compound tank, with 2mol/L hydrochloric acid
Solution adjusts pH to 7.5~8.0；(3) add activated carbon, dosage is 0.2~0.8wt% of parenteral solution, stir after 15min according to
Secondary 0.5 μm of stud, 0.45 μm of filter carry out being filtered to remove activated carbon；(4) finally sterilized (115 DEG C, 30min), lamp
Inspection, labeling, packaging.
The viscosimetric analysis of embodiment 5
By former triturate (prestige regards Parker), embodiment 1, the parenteral solution of embodiment 2, different temperature is heated to, uses Ping Shi
Viscosimeter determines its viscosity, as a result see the table below.
It was found from upper table result：Present invention effectively prevents Iodixanol adhesion problem, grinds product compared to original, its is anti-stick
Property is more superior.
Embodiment 6 sterilizes front and rear pH value and the measure of inorganic iodide
By former triturate (prestige regards Parker), embodiment 1, the parenteral solution of embodiment 2, at sterilising conditions (115 DEG C, 30min)
Under sterilized, investigate front and rear pH value and the index situation of change of inorganic iodide, as a result see the table below.
The present invention is understood on the basis of auxiliary material type and dosage is reduced from upper table result, and its stability and former triturate are simultaneously
No significant difference, even better than original grind product.
The low temperature freezing-thawing test of embodiment 7
Because Iodixanol injection fluid viscosity is larger, in order to verify its stability during transport or use, according to
Chemicals stability study technological guidance's principle, has carried out low temperature frozen process experiment, specific method is as follows respectively：
1) low-temperature test includes circulating three times, circulates in 2~8 DEG C of refrigerator cold-storages and places 2 days every time, then in 40 DEG C of drums
Investigated 2 days in wind drying box, sampling detection.
2) freezing-thawing test includes circulating three times, circulates in -10~-20 DEG C of refrigerator freezings and places 2 days every time, then 40
DEG C air dry oven is investigated 2 days, sampling detection.
Embodiment 1 and city original triturate (prestige is depending on Parker) low temperature freeze thawing result of the test see the table below.
It was found from upper table result：Total miscellaneous content of the invention substantially reduces in low temperature test, and in freezing-thawing test, city
Selling product can not apply, and product of the present invention is more stable, be more suitable for storing in rugged environment.
The blood vessel irritation of embodiment 8 and hemolytic experiment
The present invention uses Examples 1 and 2 simultaneously, has investigated it to blood vessel irritation and hemolytic experimental study.
When parenteral solution is applied to human body, any sediment in blood is likely to cause serious safety problem.Cause
This, we evaluate physical stability of the parenteral solution in rabbit erythrocyte suspension.
Hemolytic test：Appropriate parenteral solution is added into 0.5mL to be added in 2% rabbit erythrocyte suspension, Continuous Observation 10h,
There is haemolysis in each Guan Junwei.
Sensitivity test：The auricular vein of appropriate injection in Guinea-pigs is carried out to the test of sensitivity response, through exciting twice
After administration, do not observe and search, roll up, erect the sensitization phenomenons such as hair, expiratory dyspnea, death, show：The parenteral solution is to tested dynamic
Thing is without sensitization.
Vascular stimulation tests：Tested for rabbit auricular vein, above-mentioned parenteral solution physiological saline made into solvent control,
Right side ear vein administration, left side ear is solvent control, and to white big ear rabbit, daily ear vein is administered once respectively, for three days on end, in
24h after last dose, animal is put to death, takes cardinal vein, formaldehyde is fixed, disease inspection.As a result show, successive administration 3 days, visible blood under mirror
Tube wall is complete, and cell is clear, has no other obvious abnormal changes, no necrosis or tissue degeneratiaon's reaction.With the ear vein compareed
Compare, without obvious pathology morphological differences.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not limited to the substantial technological content of the present invention,
The substantial technological content of the present invention is that the right for being broadly defined in application collects, and any technology that other people complete is real
Body or method, if with the right of application defined in it is identical, also or a kind of equivalent change, will be by
It is considered as and is covered by among present claims scope.
Claims (9)
1. a kind of parenteral solution of Iodixanol, it is characterised in that contain in per 100mL parenteral solutions：
55~66g of Iodixanol
90~120mg of sodium chloride
100~200mg of sodium tartrate
Add acid for adjusting pH to 6.5~8.5
Water for injection adds to 100mL.
2. parenteral solution according to claim 1, it is characterised in that " acid " for adding regulation pH is selected from：Tartaric acid, phosphorus
Acid, one kind in hydrochloric acid；And add acid for adjusting pH value scope be pH 6.9~7.6.
3. parenteral solution according to claim 2, it is characterised in that the acid of described addition is selected from tartaric acid, and pH is arrived in regulation
The scope of value is 7.2~7.4.
4. parenteral solution according to claim 3, it is characterised in that contain in per 100mL parenteral solutions：
Iodixanol 55g
Sodium chloride 94mg
Sodium tartrate 110mg
Appropriate tartaric acid, adjust pH to pH 7.2~7.4
Water for injection adds to 100mL.
5. parenteral solution according to claim 3, it is characterised in that contain in per 100mL parenteral solutions：
Iodixanol 65.2g
Sodium chloride 115mg
Sodium tartrate 130mg
Appropriate tartaric acid, adjust pH to 7.2~7.4
Water for injection adds to 100mL.
A kind of 6. method for preparing the parenteral solution as any one of claim 1-5, it is characterised in that include following step
Suddenly：
(1) water for injection boiled of a quarter is added in Agitation Tank, 58~63 DEG C is cooled to, puts into the winestone of recipe quantity
After sour sodium stirring and dissolving 0.5h, Iodixanol, stirring and dissolving are put into batches；(2) 35~40 DEG C are cooled to, is added in material-compound tank
Enter the sodium chloride of recipe quantity, while mend and add to the full amount of water for injection into material-compound tank, add acid for adjusting pH to 6.9~7.6, it is described
Acid is selected from tartaric acid, one kind in hydrochloric acid or phosphoric acid；(3) activated carbon is added, dosage is 0.2~0.8wt% of parenteral solution, is stirred
Carry out being filtered to remove activated carbon with 0.5 μm of stud, 0.45 μm of filter successively after mixing 15min；(4) finally sterilized at 115 DEG C
30min, lamp inspection, labeling, packaging.
7. preparation method according to claim 6, it is characterised in that the acid for adjusting pH value is selected from tartaric acid, and pH is arrived in regulation
The scope of value is 7.2~7.4.
8. parenteral solution according to any one of claims 1 to 5 is preparing the application among x-ray contrast agent.
9. application according to claim 8, it is characterised in that the x-ray contrast agent can be applied to angiocardiography, brain blood
Pipe radiography, peripheral arterial radiography, abdominal angiography, IVU, phlebography and CT enhancings check.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510513894.9A CN105106976B (en) | 2015-08-20 | 2015-08-20 | A kind of Iodixanol parenteral solution and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510513894.9A CN105106976B (en) | 2015-08-20 | 2015-08-20 | A kind of Iodixanol parenteral solution and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105106976A CN105106976A (en) | 2015-12-02 |
| CN105106976B true CN105106976B (en) | 2018-03-30 |
Family
ID=54655238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510513894.9A Active CN105106976B (en) | 2015-08-20 | 2015-08-20 | A kind of Iodixanol parenteral solution and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106976B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105664182A (en) * | 2016-01-29 | 2016-06-15 | 李�杰 | Preparation method of injection of contrast agent iodixanol |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169988A (en) * | 2011-12-23 | 2013-06-26 | 中央医疗服务有限公司 | Contrast medium composition with contrast enhancement effect by comprising highly concentrated agent |
| DE102012001146A1 (en) * | 2012-01-21 | 2013-07-25 | Bayer Intellectual Property Gmbh | Use of mannitol-/glucose mixture for producing drugs having diuretic effect during administration, preferably intravenous administration of iodinated X-ray contrast agent |
-
2015
- 2015-08-20 CN CN201510513894.9A patent/CN105106976B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169988A (en) * | 2011-12-23 | 2013-06-26 | 中央医疗服务有限公司 | Contrast medium composition with contrast enhancement effect by comprising highly concentrated agent |
| DE102012001146A1 (en) * | 2012-01-21 | 2013-07-25 | Bayer Intellectual Property Gmbh | Use of mannitol-/glucose mixture for producing drugs having diuretic effect during administration, preferably intravenous administration of iodinated X-ray contrast agent |
Non-Patent Citations (2)
| Title |
|---|
| "Iodixanol(Optiprep),an improved density gradient medium for the Iso-osmotic isolation or rat liver peroxisomes";Paul P. Van Veldhoven等;《Analytic biochemistry》;19961231(第237期);第17-23页 * |
| "碘克沙醇-一种新型的更安全的对比剂";卞读军等;《放射学实践》;20050520(第313期);第458-459页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105106976A (en) | 2015-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11724022B2 (en) | Tailored dose of contrast agent | |
| CN102160852A (en) | Ibuprofen injection and preparation method thereof | |
| CN102836171B (en) | Solution for surgery and endoscope washing and preparation method thereof | |
| CN105476955B (en) | A kind of isosorbide dinitrate injection and preparation method thereof | |
| CN105106976B (en) | A kind of Iodixanol parenteral solution and preparation method thereof | |
| CN105997852B (en) | A kind of Rui Jianuosheng injections and preparation method thereof | |
| CN105769756B (en) | A kind of fumaric acid Sitafloxacin hydrate injection and preparation method thereof | |
| KR20170017522A (en) | Chitosan-chelator hydrogel for treating cancer and method to prepare the same, and pharmaceutical composition and embolotherapy composition comprising the same | |
| CN102512379B (en) | A kind of novel Echinocandin antifungal pharmaceutical composition and preparation method thereof | |
| WO2020248648A1 (en) | Ornidazole injection and s-ornidazole injection | |
| CN105287370B (en) | A kind of preparation method of inosine and combinations thereof composition injection | |
| CN100560068C (en) | The preparation method of Levogyration sulpiride injection and its | |
| CN100386078C (en) | Nimodipine emulsion injection liquid and method for preparing the same | |
| CN103784438B (en) | A kind of Amino Acid Compound Injection-HBC composition and method of making the same | |
| CN105125480A (en) | Lipoic acid liquid preparation and preparation method thereof | |
| CN103800323B (en) | A kind of Amino Acid Compound Injection 18AA-V composition and method of making the same | |
| CN105640985A (en) | Peritoneal dialysis fluid (lactate) (low-calcium) medicinal composition | |
| CN104997728B (en) | A kind of Nalmefene hydrochloride injection pharmaceutical composition and preparation method thereof | |
| CN109528632A (en) | Nimodipine pharmaceutical composition, nimotop vial and preparation method thereof | |
| CN107789365A (en) | The medical composition and its use of various trace elements V | |
| CN103961310B (en) | A kind of carbazochrime sodium sulfonate injection and preparation method thereof | |
| AU2014241494B2 (en) | Method and reagent for preparing a diagnostic composition | |
| CN102772373B (en) | A kind of injection vinorelbine tartrate injectable powder and preparation method thereof | |
| RU2776412C2 (en) | CONTRAST COMPOSITION FOR MAGNETIC RESONANCE IMAGING AND ANGIOGRAPHY BASED ON Mn-DCTA | |
| CN104042602A (en) | Application of sodium glutamate in puerarin injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 210038 9 Hui Ou Road, Nanjing economic and Technological Development Zone, Jiangsu Patentee after: NANJING CHIA TAI TIANQING PHARMACEUTICAL Co.,Ltd. Patentee after: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Address before: 210038 9 Hui Ou Road, Nanjing economic and Technological Development Zone, Jiangsu Patentee before: NANJING CHIA TAI TIANQING PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING HAIRONG PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210519 Address after: 210038 9 Hui Ou Road, Nanjing economic and Technological Development Zone, Jiangsu Patentee after: NANJING CHIA TAI TIANQING PHARMACEUTICAL Co.,Ltd. Address before: 210038 9 Hui Ou Road, Nanjing economic and Technological Development Zone, Jiangsu Patentee before: NANJING CHIA TAI TIANQING PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right |